(Q35570248)

English

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

scientific article published on 6 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

adaptive radiation therapy

0 references

pharmacogenomics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Bruno M Costa

13

0 references

Rui Manuel Reis

object named as

Rui M Reis

14

0 references

author name string

Nicholas Butowski

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Susan M Chang

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Kathleen R Lamborn

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Mei-Yin Polley

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Russell Pieper

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Joseph F Costello

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Scott Vandenberg

7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Rupa Parvataneni

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Angelina Nicole

9

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Patricia K Sneed

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jennifer Clarke

11

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Emily Hsieh

12

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Maria Hristova-Kazmierski

15

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Steven J Nicol

16

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Donald E Thornton

17

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Michael D Prados

18

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

publication date

6 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1331-1338

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Chemoradiotherapy in malignant glioma: standard of care and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

New approaches to molecular cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Methylation sequencing from limiting DNA: embryonic, fixed, and microdissected cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Protein kinase C targeting in antineoplastic treatment strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

12 July 2018

Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Synergistic antiglioma activity of radiotherapy and enzastaurin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

26 September 2018

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223090

24 October 2018

Predicting lung cancer by detecting aberrant promoter methylation in sputum

1 reference

https://pubmed.ncbi.nlm.nih.gov/21896554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21896554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NEUONC/NOR130

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35570248&oldid=1534103556"